MA31663B1 - Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe - Google Patents

Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe

Info

Publication number
MA31663B1
MA31663B1 MA32377A MA32377A MA31663B1 MA 31663 B1 MA31663 B1 MA 31663B1 MA 32377 A MA32377 A MA 32377A MA 32377 A MA32377 A MA 32377A MA 31663 B1 MA31663 B1 MA 31663B1
Authority
MA
Morocco
Prior art keywords
reversible
intervasive
inhibitor
oral
dosage
Prior art date
Application number
MA32377A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Phillips
Anjali Pandey
Huang Wolin
Robert M Scarborough
Original Assignee
Portoal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portoal Pharmaceuticals Inc filed Critical Portoal Pharmaceuticals Inc
Publication of MA31663B1 publication Critical patent/MA31663B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés et des compositions pour l'inhibition rapide et réversible de l'agrégation plaquettaire chez des sujets humains en ayant besoin par administration de composés de formule : (i) seuls ou en combinaison avec un second agent qui peut être de l'aspirine ou un agent thrombolytique.
MA32377A 2007-05-02 2009-11-26 Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe MA31663B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (fr) 2007-05-02 2008-05-02 Dosage oral et intraveineux de l'inhibiteur p2y12 réversible et à action directe

Publications (1)

Publication Number Publication Date
MA31663B1 true MA31663B1 (fr) 2010-09-01

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32377A MA31663B1 (fr) 2007-05-02 2009-11-26 Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe

Country Status (17)

Country Link
US (2) US20090048216A1 (fr)
EP (1) EP2079464A2 (fr)
JP (1) JP2010526101A (fr)
KR (1) KR20100029746A (fr)
CN (1) CN101795682A (fr)
AU (1) AU2008247483A1 (fr)
BR (1) BRPI0811476A2 (fr)
CA (1) CA2686203A1 (fr)
CO (1) CO6241104A2 (fr)
EA (1) EA200901473A1 (fr)
EC (1) ECSP099778A (fr)
GT (1) GT200900284A (fr)
IL (1) IL201834A0 (fr)
MA (1) MA31663B1 (fr)
MX (1) MX2009011843A (fr)
TN (1) TN2009000451A1 (fr)
WO (1) WO2008137753A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
MX2009009492A (es) * 2007-03-06 2009-09-15 Novartis Ag Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas.
BRPI0810800A2 (pt) * 2007-05-02 2014-10-29 Portola Pharm Inc Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles.
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
RU2011132125A (ru) * 2008-12-30 2013-02-10 Тромбологик Апс Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PT2498731T (pt) 2009-11-11 2020-02-21 Chiesi Farm Spa Métodos de tratamento ou prevenção de uma trombose de endoprótese
US8663661B2 (en) * 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (fr) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Formes galéniques de l'élinogrel et leurs méthodes d'administration injectables
EP2646827A1 (fr) * 2010-12-01 2013-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé et trousses pour déterminer la sensibilité des plaquettes à une activation dans un patient
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
US11260071B2 (en) 2017-06-23 2022-03-01 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법

Also Published As

Publication number Publication date
CN101795682A (zh) 2010-08-04
ECSP099778A (es) 2010-01-29
MX2009011843A (es) 2010-04-22
IL201834A0 (en) 2010-06-16
GT200900284A (es) 2012-01-31
WO2008137753A3 (fr) 2009-02-12
EP2079464A2 (fr) 2009-07-22
EA200901473A1 (ru) 2010-06-30
US20090048216A1 (en) 2009-02-19
KR20100029746A (ko) 2010-03-17
CO6241104A2 (es) 2011-01-20
WO2008137753A2 (fr) 2008-11-13
AU2008247483A1 (en) 2008-11-13
TN2009000451A1 (en) 2011-03-31
BRPI0811476A2 (pt) 2014-11-04
CA2686203A1 (fr) 2008-11-13
US20120009172A1 (en) 2012-01-12
JP2010526101A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
EP2101757A4 (fr) Composé pour le traitement ou la prévention de maladies en relation avec la prostate et compositions pharmaceutiques de système d'administration par le colon contenant ce composé
EP1965823A4 (fr) Procedes d'administration d'agents hypoglycemiques
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA33571B1 (fr) Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
MA30765B1 (fr) Derives innovants du thiophene
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
EP1781257A4 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2007044085A3 (fr) Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
DK1819227T3 (da) Farmaceutisk formulering af decitabin
MY151295A (en) Pyrimidyl indoline compound
ATE554770T1 (de) Therapeutisches mittel gegen entzündliche darmerkrankungen
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы